{"commentary":{"count":18,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":9,"youtube":7,"podcast":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06520345\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT06520345","nct_id":"NCT06520345","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06520345. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Lutetium (177Lu) rosopatamab tetraxetan (177Lu-TLX591) 76 mCi (±10%) given approximately 14 days apart, plus SOC.\n\nSOC is either:\n\nConcurrent enzalutamide (starting dose 160 mg daily) + prednisone / prednisolone (5 mg twice a day) or equivalent.\n\nor\n\nConcurrent abiraterone (starting dose 1,000 mg daily) + prednisone / prednisolone (5 mg once daily for the standard formulation), methylprednisolone (4 mg twice daily for the fine particle formulation) or dexamethasone (1 mg once daily)\n\nor\n\nSequential Docetaxel: Single agent chemotherapy will consist of docetaxel given at a recommended dose of 75mg/m2 IV every 3 weeks given in combination with oral prednisone / prednisolone (5mg twice a day) or equivalent for up to 10 cycles.","label":"177Lu-TLX591 + Enzalutamide or Abiraterone or Docetaxel","type":"EXPERIMENTAL"},{"description":"SOC is either:\n\nEnzalutamide (starting dose 160 mg daily).\n\nor\n\nAbiraterone (starting dose 1,000 mg daily) + prednisone / prednisolone (up to 10 mg once daily for the standard formulation)\n\nor\n\nDocetaxel: Single agent chemotherapy will consist of docetaxel given at a recommended dose of 75mg/m2 IV every 3 weeks given in combination with oral prednisone / prednisolone 5mg twice a day (or equivalent) for up to 10 cycles","label":"Control Arm (Enzalutamide or Abiraterone or Docetaxel)","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2030-12","type":"ESTIMATED"},"conditions":["Metastatic Castration-resistant Prostate Cancer"],"enrollment":{"count":520,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"177Lu-TLX591","type":"DRUG"},{"name":"Enzalutamide","type":"DRUG"},{"name":"Abiraterone","type":"DRUG"},{"name":"Docetaxel","type":"DRUG"}],"last_update":"2026-07-21","lead_sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","official_title":"A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lutetium (177Lu) Rosopatamab Tetraxetan in Combination With Standard of Care Versus Standard of Care Alone in Patients With PSMA Positive Metastatic Castration-Resistant Prostate Cancer Previously After Androgen Receptor Pathway Inhibitor Treatment","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-12","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Radiographic Progression-free Survival","timeFrame":"337days"}],"references":[],"start_date":{"date":"2024-07-26","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)","url":"https://clinicaltrials.gov/study/NCT06520345"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06520345"}